Business
Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices
Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices Canada NewsWire ...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"\n\n\n\n Wall Street Eyes Breakout Cancer Therapies Amid Soaring Drug Prices\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n\n\n\n\n\n Canada NewsWire\n \n\n\n\n\n\n Equity Insider\n \n\n\n News Commentary\n \n\n\n\n\n Issued on behalf of Oncolytics Biotech Inc.\n \n\n\n\n\n\n VANCOUVER, BC\n \n\n ,\n \n\n June 24, 2025\n \n\n /CNW/ --\n \n\n Equity Insider\n \n\n\n News Commentary\n \n – Rising rates of cancer are going to come at a major cost, and it's looking more and more like the solution is going to have to come from the private sector. Recent\n \n reports\n \n suggest the U.S. government may slash\n \n National Cancer Institute (NCI)\n \n funding\n \n by nearly 40%,\n \n while\n \n Bloomberg\n \n reports growing concern over affordability and access to\n \n cancer drugs\n \n whose prices are rising sharply. From Wall Street's point of view, the focus needs to shift towards up-and-coming treatments being developed by promising candidates, including from\n \n Oncolytics Biotech Inc.\n \n (NASDAQ: ONCY) (TSX: ONC),\n \n Indaptus Therapeutics, Inc.\n \n (NASDAQ: INDP),\n \n Perspective Therapeutics, Inc.\n \n (NYSE-American: CATX),\n \n SELLAS Life Sciences Group, Inc.\n \n (NASDAQ: SLS), and\n \n Autolus Therapeutics plc\n \n (NASDAQ: AUTL).\n \n\n\n\n\n\n\n\n Analysts at\n \n Nova One Advisor\n \n are currently projecting the\n \n global oncology drug market\n \n to hit\n \n US$366.24 billion\n \n by 2034, expanding at a 7.4% CAGR. Others are even more optimistic, with\n \n ResearchAndMarkets\n \n\n estimating\n \n the sector will reach\n \n US$866.1 billion\n \n by 2034, growing at a 10.8% CAGR, and\n \n Vision Research Reports\n \n\n anticipating the market\n \n will top\n \n US$903.81 billion\n \n by the same year, driven by accelerating demand for advanced diagnostics and treatments. All this points to an optimal timing period for breakout cancer stocks.\n \n\n\n Oncolytics Biotech Inc.\n \n (NASDAQ: ONCY) (TSX: ONC) has entered a new chapter with the\n \n appointment\n \n of\n \n Jared Kelly\n \n as Chief Executive Officer and member of the Board. With ...